Skip to main content

Table 3 Treatment exposure by history of calcinosis

From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis

Risk factor Descriptive analysis    Univariable analysis
Calcinosis   OR [95% CI] p-value
Yes No
Biologic treatment (Ever) n (%)    
 Any biologic 48 (57.1) 194 (35.5) 0.0001 2.426 [1.522–3.867]  
 Rituximab 12 (14.3) 14 (2.6) < 0.0001 6.345 [2.825–14.254] < 0.001
 IV Immune Globulin 45 (53.6) 180 (32.9) 0.0002 2.353 [1.479–3.743] 0.0003
 Anti-TNF 12 (14.3) 23 (4.2) 0.0009 3.797 [1.812–7.960] 0.0004
 Abatacept 2 (2.4) 1 (0.2) 0.048 13.317 [1.194–148.514] 0.0354
 Anti-IL1 1 (1.2) 1 (0.2)    
High steroid exposure 47 (56) 269 (54.3)